India Influenza Vaccine Market Size & Outlook, 2024-2030
The influenza vaccine market in India is expected to reach a projected revenue of US$ 477.8 million by 2030. A compound annual growth rate of 10.2% is expected of India influenza vaccine market from 2024 to 2030.
In terms of revenue, India accounted for 3.1% of the global influenza vaccine market in 2023.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
In Asia Pacific, China influenza vaccine market is projected to lead the regional market in terms of revenue in 2030.
India is the fastest growing regional market in Asia Pacific and is projected to reach USD 477.8 million by 2030.
India has a flourishing pharmaceutical sector owing to the emergence of generic manufacturers and the presence of leading pharmaceutical players. The growth of India influenza vaccine market is driven by increasing prevalence of influenza in the country, coupled with several awareness campaigns arranged by governments to promote awareness regarding the condition.
In addition, rising government efforts to bring next-generation influenza vaccines into the country is another factor propelling the country’s market. For instance, in August 2018, India and the EU announced a collaboration to develop a next generation flu vaccine for people in India.
Moreover, several strategic initiatives undertaken by leading participants are another factor propelling the country’s market. For instance, in February 2017, Zydus Cadila announced that it received approval to launch its tetravalent flu vaccine in India.
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Influenza Vaccine Market Outlook will help companies and investors design strategic landscapes.
Inactivated was the largest segment with a revenue share of 100.16% in 2023.
Horizon Databook has segmented the India influenza vaccine market based on inactivated, live attenuated covering the revenue growth of each sub-segment from 2018 to 2030.
India has a flourishing pharmaceutical sector owing to the emergence of generic manufacturers and the presence of leading pharmaceutical players. The growth of India influenza vaccine market is driven by increasing prevalence of influenza in the country, coupled with several awareness campaigns arranged by governments to promote awareness regarding the condition.
In addition, rising government efforts to bring next-generation influenza vaccines into the country is another factor propelling the country’s market. For instance, in August 2018, India and the EU announced a collaboration to develop a next generation flu vaccine for people in India.
Moreover, several strategic initiatives undertaken by leading participants are another factor propelling the country’s market. For instance, in February 2017, Zydus Cadila announced that it received approval to launch its tetravalent flu vaccine in India.
India Influenza Vaccine Market Vaccine Type Outlook (Revenue, USD Million , 2018-2030)
Inactivated
Live Attenuated
India Influenza Vaccine Market Indication Outlook (Revenue, USD Million , 2018-2030)
Quadrivalent
Trivalent
India Influenza Vaccine Market Age Group Outlook (Revenue, USD Million , 2018-2030)
Pediatric
Adult
India Influenza Vaccine Market Route of Administration Outlook (Revenue, USD Million , 2018-2030)
Injection
Nasal Spray
India Influenza Vaccine Market Distribution Channel Outlook (Revenue, USD Million , 2018-2030)
Hospitals & Pharmacy
Government & Institutional supply
Other Distribution Channels
Reasons to subscribe to Influenza Vaccine Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Influenza Vaccine Market Outlook databook
Our clientele includes a mix of Influenza Vaccine Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the India Influenza Vaccine Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into India Influenza Vaccine Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.